Integra Lifesciences Holdings (IART) Operating Expenses (2009 - 2026)

Integra Lifesciences Holdings' Operating Expenses history runs 18 years deep, the most recent figure standing at $380.4 million for Q1 2026.

• In Q1 2026, Operating Expenses fell 4.45% year-over-year to $380.4 million; the TTM figure through Mar 2026 stood at $2.1 billion (up 30.68% YoY), while the FY2025 annual figure was $2.1 billion, up 34.54% from the prior year.
• Operating Expenses came in at $380.4 million for Q1 2026 at Integra Lifesciences Holdings, down from $411.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $928.3 million in Q2 2025 to a low of $320.1 million in Q3 2022.
• A 5-year average of $402.4 million and a median of $368.8 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses decreased 4.93% in 2022 and soared 120.39% in 2025, its largest moves.
• Integra Lifesciences Holdings' Operating Expenses stood at $330.2 million in 2022, then gained by 9.33% to $361.0 million in 2023, then rose by 12.75% to $407.0 million in 2024, then climbed by 1.2% to $411.9 million in 2025, then dropped by 7.63% to $380.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $380.4 million, $411.9 million, and $390.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison